This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Walmart files US price-fixing claims against generic pharmaceutical companies

( March 14, 2025, 19:39 GMT | Official Statement) -- MLex Summary: Walmart filed a US complaint accusing Actavis, Alvogen, Amneal and other generic pharmaceutical companies of illegally conspiring to fix the prices of various drugs since May 2009. "[T]he defendants have deprived the public of the benefit of that bargain by entering into a series of illegal 'fair share' agreements to allocate customers and markets, engage in bid rigging, and fix the prices of hundreds of pharmaceutical products. These agreements, which are illegal per se under federal antitrust laws, led to staggering price increases for critical medications and forced consumers and their health plans to shoulder the cost of Defendants’ illegal activities," the complaint alleges. See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections